SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following reports that the company is preparing a potential acquisition of eBay, a move seen by the community as a bold, if ambitious, attempt to leverage GameStop's cash reserves for a massive retail transformation. While bullish investors are celebrating the news as a long-awaited catalyst and potential squeeze signal, skeptics are actively questioning the feasibility of financing a deal for a company significantly larger than GameStop itself.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in South Korea, Japan, and Turkey, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay is trending following a report that GameStop is building a stake in the company ahead of a potential takeover bid. While the community is actively debating the logistics and financing of such a massive acquisition, the speculation has fueled significant after-hours volatility and heightened options activity.

WorldFinancial

World Liberty Financial is facing intense backlash and downward price pressure as investors react to a government probe into its $500 million UAE deal and community concerns over governance voting. While some retail supporters are aggressively buying the dip in hopes of a short squeeze, many are actively labeling the project a grift or pump-and-dump scheme due to recent token dilution and management's perceived lack of transparency.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is capturing significant community attention as traders analyze the stock's consolidation patterns near key resistance levels, with speculation mounting over potential M&A activity and the company's critical role in the booming AI data training sector. Investors are closely monitoring the technical setup for a possible breakout while actively debating the impact of increased institutional options activity and the company's strategic positioning within the evolving AI infrastructure landscape.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXT Inc. is trending as investors weigh its role as a key substrate supplier for AI-focused data centers against concerns over its parabolic valuation and recent share dilution. The community remains sharply divided, with bulls pointing to institutional interest and the critical nature of its indium phosphide technology, while bears highlight the company's lack of consistent profitability and reliance on FOMO-driven retail participation.

Ethereum Classic

Ethereum Classic is experiencing a surge in social media activity and trending status, as community members debate whether this move signals a sustainable reversal or another speculative trap. Discussion is heavily focused on the coin's long-term utility as an original PoW blockchain, with many retail investors expressing deep frustration over prolonged periods of stagnant performance while comparing it against more volatile altcoins.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

Fannie Mae (FNMA) is rallying sharply following influential investor commentary, including Bill Ackman describing the shares as deeply undervalued with significant potential upside. The community is actively discussing the stock's long-term privatization prospects and the potential for an IPO or release from conservatorship, leading to high volume and speculation about major upcoming policy announcements.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is drawing significant attention as institutional accumulation intensifies, highlighted by major treasury purchases from firms like BitMine and continued institutional interest via spot ETFs. Market participants are actively debating the potential impact of the proposed Clarity Act on regulatory sentiment while monitoring whether these sustained inflows and staking dynamics can drive a breakout above key psychological resistance levels.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is currently a focal point for investors due to surging demand for high-speed optical transceivers, with the community actively debating whether the stock's parabolic climb is a fundamental re-rating driven by AI data center infrastructure or an overextended speculative bubble. Discussion is polarized between those highlighting significant order backlogs and capacity expansions as long-term catalysts, and those raising concerns about high valuations and potential volatility surrounding upcoming earnings.

McDonald's Corp. engages in the operation and franchising of restaurants. It operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. The firm's products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, McCafe beverages, and other beverages. The company was founded by Raymond Albert Kroc on April 15, 1955, and is headquartered in Oak Brook, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is currently a hot topic as investors analyze its aggressive international expansion and value-focused menu initiatives meant to drive customer traffic. The community remains divided, with active debates centered on the brand's long-term growth potential and the leadership's effectiveness in balancing menu pricing with customer sentiment.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Short Interest in Edesa Biotech, Inc. (NASDAQ:EDSA) Decreases By 32.5%

Edesa Biotech, Inc. (NASDAQ:EDSA - Get Free Report) saw a large decline in short interest in April. As of April 15th, there was short interest totaling 267,664 shares, a decline of 32.5% from the...

<ul class="summary-bullets"><li>The CEO will present findings from Edesa’s late-stage study of EB05, being evaluated as a treatment for Acute Respiratory Distress Syndrome (ARDS), at the conference.</li><li>The company expects to start recruiting patients for its mid-stage vitiligo trial starting in mid-2026.</li><li>According to data from &nbsp;Koyfin, both analysts covering EDSA rate it ‘Buy.’</li></ul> Shares of Edesa Biotech (EDSA) rallied 54% higher on Monday, closing at a new 52-week high of $11.17. &nbsp;The rally comes ahead of the company CEO’s upcoming presentation at the ATS 2026 Respiratory Innovation Summit (RIS), organized by the American Thoracic Society (ATS), on May 15. The CEO will present findings from Edesa’s late-stage study of EB05, being evaluated as a treatment for Acute Respiratory Distress Syndrome (ARDS), at the conference.In February, Edesa reported positive late-stage trial results for EB05. The company said that the drug demonstrated statistically significant reductions in 28-day mortality across a broader patient population in the trial. &nbsp;<h2 class="st-heading-2">Remaining Pipeline</h2>Edesa is a biopharmaceutical company developing treatments for inflammatory and immune-related diseases. The company’s pipeline includes EB06, being developed as a therapy for vitiligo, and EB01 for the treatment of moderate-to-severe chronic Allergic Contact Dermatitis.Last month, the company said that it expects to start recruiting patients for its mid-stage vitiligo trial starting in mid-2026. The trial is aimed at evaluating the safety and efficacy of EB06 compared to adults in adults with with generalized vitiligo.<h2 class="st-heading-2">Analyst Takeaway</h2>According to data from &nbsp;Koyfin, both analysts covering EDSA rate it ‘Buy.’The average 12-month price target on the stock is $11, representing a potential downside of about 2%.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around EDSA stock jumped from ‘bearish’ to ‘bullish’ territory while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user speculated a buyout price for the company.<stembedurl>https://www.stocktwits.com/VoxChameleon/message/651560849</stembedurl><a href="https://stocktwits.com/symbol/EDSA">EDSA stock</a> has gained 365% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tsla-overvalued-fund-manager-demands-math-on-3000-dollar-bull-targets/cZBV5nGRePu">TSLA Overvalued? Fund Manager Demands Math on $3,000 Bull Targets</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

EDSA Stock Rallied Over 50% Today: What’s Ahead For The Small-Cap Biotech?

The rally comes ahead of the company CEO’s upcoming presentation at the ATS 2026 Respiratory Innovation Summit (RIS) and other pipeline catalysts.

EDSA Stock Rallied Over 50% Today: What’s Ahead For The Small-cap Biotech?

Equity

Edesa Biotech (NASDAQ:EDSA) Rating Increased to Hold at Wall Street Zen

Wall Street Zen raised Edesa Biotech from a "sell" rating to a "hold" rating in a research note on Sunday...

Short Interest in Edesa Biotech, Inc. (NASDAQ:EDSA) Expands By 9,253.7%

Edesa Biotech, Inc. (NASDAQ:EDSA - Get Free Report) saw a significant increase in short interest during the month of February. As of February 27th, there was short interest totaling 1,411,103 shares...

Best Biotech Stocks To Follow Today - March 7th

Danaher, Moderna, Vertex Pharmaceuticals, argenex, Iovance Biotherapeutics, Edesa Biotech, and ImmunityBio are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool...

Pardeep Nijhawan Purchases 10,000 Shares of Edesa Biotech (NASDAQ:EDSA) Stock

Edesa Biotech, Inc. (NASDAQ:EDSA - Get Free Report) CEO Pardeep Nijhawan purchased 10,000 shares of Edesa Biotech stock in a transaction dated Thursday, March 5th. The shares were purchased at an...

Edesa Biotech (NASDAQ:EDSA) CEO Pardeep Nijhawan Acquires 10,000 Shares

Edesa Biotech, Inc. (NASDAQ:EDSA - Get Free Report) CEO Pardeep Nijhawan purchased 10,000 shares of the firm's stock in a transaction on Thursday, March 5th. The shares were acquired at an average...

Edesa Biotech (NASDAQ:EDSA) CEO Buys $36,300.00 in Stock

Edesa Biotech, Inc. (NASDAQ:EDSA - Get Free Report) CEO Pardeep Nijhawan acquired 10,000 shares of the business's stock in a transaction dated Tuesday, March 3rd. The stock was acquired at an average...

Pardeep Nijhawan Acquires 30,000 Shares of Edesa Biotech (NASDAQ:EDSA) Stock

Edesa Biotech, Inc. (NASDAQ:EDSA - Get Free Report) CEO Pardeep Nijhawan purchased 30,000 shares of the business's stock in a transaction on Friday, February 27th. The shares were purchased at an...

<ul class="summary-bullets"><li>The company on Tuesday reported results from a 278-patient population, including 104 patients requiring invasive mechanical ventilation (IMV) as well as 174 non-IMV patients.</li><li>Overall rates of adverse events, serious adverse events, infections and treatment discontinuations were low and similar between the paridiprubart and placebo groups, the company said.&nbsp;</li><li>The company is advancing regulatory discussions and evaluating strategic collaborations and partnership opportunities, the CEO said.</li></ul>Shares of Edesa Biotech, Inc. jumped 76% on Tuesday after the company announced that data from a late-stage study of its experimental drug for the treatment of Acute Respiratory Distress Syndrome affirmed statistically significant mortality reductions.Acute respiratory distress syndrome (ARDS) is a life-threatening, rapid-onset lung failure caused by severe inflammation, which fills the air sacs with fluid and restricts oxygen absorption.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/02/24/3243711/0/en/Edesa-Biotech-Reports-Additional-Positive-Results-from-Phase-3-Paridiprubart-Study.html">reported</a> results from a 278-patient population, including 104 patients requiring invasive mechanical ventilation (IMV) as well as 174 non-IMV patients.Edesa Biotech said that its experimental drug paridiprubart demonstrated statistically significant reduction in 28-day mortality in the full population to 24% from 33%.Further, treatment benefits were consistent across severity groups and in patients with serious comorbidities. Overall rates of adverse events, serious adverse events, infections, and treatment discontinuations were low and similar between the paridiprubart and placebo groups, the company said. &nbsp;<h2 class="st-heading-2">CEO Expresses Optimism</h2>“The consistency of mortality reduction and clinical improvement across all 278 randomized patients, including less severe patients as well as those with ARDS complicated by acute kidney injury, sepsis and pneumonia, underscores the versatility and transformative potential of paridiprubart to address multiple critical unmet medical needs,” said CEO Par Nijhawan.The chief also added that the company is advancing regulatory discussions and evaluating strategic collaborations and partnership opportunities which could potentially accelerate development.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around EDSA stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.A Stocktwits user said that they are now waiting for that “first real surge” in stock price.<stembedurl>https://www.stocktwits.com/topstockalerts/message/645761015</stembedurl><a href="https://stocktwits.com/symbol/EDSA">EDSA stock</a> has dropped 29% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/ark-cathie-wood-rebuts-citrini-ai-thought-piece/cZRw3pOR4Cp">ARK’s Cathie Wood Rebuts Citrini AI Thought Piece, Predicts Opportunities After Near-Term Disruptions</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did EDSA Stock Rally More Than 70% Today?

Edesa Biotech said that data from a late-stage study of its experimental drug for the treatment of Acute Respiratory Distress Syndrome affirmed statistically significant mortality reductions.

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquisition, development, and commercialization of drug candidates for medical dermatology and respiratory diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.

EDSA
Edesa Biotech Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest EDSA News

EDSAEdesa Biotech Inc